Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima Sells 20,000 Shares

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 20,000 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total transaction of $792,200.00. Following the transaction, the chief operating officer now directly owns 982,442 shares in the company, valued at approximately $38,914,527.62. This trade represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Ryan Fukushima also recently made the following trade(s):

• On Monday, December 16th, Ryan Fukushima sold 3,500 shares of Tempus AI stock. The shares were sold at an average price of $40.23, for a total transaction of $140,805.00.
• On Wednesday, December 11th, Ryan Fukushima sold 120,000 shares of Tempus AI stock. The shares were sold at an average price of $42.51, for a total transaction of $5,101,200.00.

Tempus AI Trading Down 3.6 %

Shares of Tempus AI stock opened at $37.49 on Thursday. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $79.49. The business’s fifty day moving average is $48.59 and its two-hundred day moving average is $46.96.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on TEM shares. Guggenheim assumed coverage on Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 price target on the stock. Wolfe Research began coverage on Tempus AI in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. Loop Capital increased their price objective on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Bank of America lifted their target price on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Finally, Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and increased their price target for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, Tempus AI currently has a consensus rating of “Moderate Buy” and an average target price of $56.00.

Institutional Trading of Tempus AI

A number of hedge funds have recently added to or reduced their stakes in TEM. Pier Capital LLC acquired a new stake in Tempus AI during the second quarter worth about $2,301,000. Federated Hermes Inc. purchased a new position in Tempus AI in the second quarter valued at approximately $19,886,000. Revolution Growth Management Company Inc. acquired a new position in Tempus AI in the 2nd quarter worth $128,133,000. Allen Operations LLC acquired a new stake in shares of Tempus AI during the second quarter valued at about $3,831,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Tempus AI in the second quarter worth about $634,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.